検索結果

sual impairment, resulting in less than 0.1 in decimal visual acuity(1) . However, no guidelines or evidence-based therapies have been established anywhere in the world for CRAO(2) . Senju will work d...

Product Development Policy | Research & Development | SENJU Pharmaceutica

e (4.65 million people in Japan) and is expected to increase in the future #7, 8. The only reliable evidence-based treatment is a decrease of ocular pressure. Treatment options include drug therapy (e...

sual impairment, resulting in less than 0.1 in decimal visual acuity 1) . However, no guidelines or evidence-based therapies have been established in the world for CRAO2) . Senju will work diligently ...

sual impairment, resulting in less than 0.1 in decimal visual acuity 1) . However, no guidelines or evidence-based therapies have been established in the world for CRAO2) . Senju will work diligently ...

ルミガン点眼液0.03％

or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncerta...